Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BBLGW
Upturn stock ratingUpturn stock rating

Bone Biologics Corp Warrants (BBLGW)

Upturn stock ratingUpturn stock rating
$15
Last Close (24-hour delay)
Profit since last BUY-79.95%
upturn advisory
SELL
SELL since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/18/2025: BBLGW (1-star) is a SELL. SELL since 3 days. Profits (-79.95%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$15
high$

Analysis of Past Performance

Type Stock
Historic Profit -89.83%
Avg. Invested days 27
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/18/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.28
52 Weeks Range 3.00 - 95.04
Updated Date 06/28/2025
52 Weeks Range 3.00 - 95.04
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.14

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -77.73%
Return on Equity (TTM) -129.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 537318
Shares Outstanding -
Shares Floating 537318
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bone Biologics Corp Warrants

stock logo

Company Overview

overview logo History and Background

Bone Biologics Corp (BBLG) is a development-stage biotechnology company. Information on the warrants is limited, but warrants are often issued in conjunction with an offering of stock or other securities, representing the right to purchase additional shares at a specified price within a specific timeframe.

business area logo Core Business Areas

  • Orthobiologics: Bone Biologics is focused on orthobiologics, specifically developing products for bone regeneration.

leadership logo Leadership and Structure

Information on Bone Biologics Corp's leadership and organizational structure is limited. Refer to the company's website or SEC filings for detailed information.

Top Products and Market Share

overview logo Key Offerings

  • NBG-002: NBG-002 is Bone Biologics' lead product candidate, a bone graft substitute intended to promote bone regeneration. Market share data is not readily available. Competitors include Medtronic, Johnson & Johnson, and Stryker in the bone graft market.

Market Dynamics

industry overview logo Industry Overview

The orthobiologics market is growing due to the aging population, increasing demand for minimally invasive procedures, and advancements in regenerative medicine.

Positioning

Bone Biologics is a small player in a competitive orthobiologics market. Its success depends on the clinical and commercial viability of NBG-002.

Total Addressable Market (TAM)

The global orthobiologics market is estimated in the billions of dollars. Bone Biologics' TAM depends on the specific indications NBG-002 targets and its market penetration. Given its development stage, their current positioning represents a very small fraction of the total available market.

Upturn SWOT Analysis

Strengths

  • Novel technology (NBG-002)
  • Potential for bone regeneration
  • Focus on a growing market

Weaknesses

  • Limited financial resources
  • Development-stage company
  • Dependence on NBG-002 success
  • Small market capitalization

Opportunities

  • Partnerships with larger companies
  • Expansion into new indications
  • Positive clinical trial results
  • FDA approval of NBG-002

Threats

  • Competition from established players
  • Regulatory hurdles
  • Clinical trial failures
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • JNJ
  • SYK

Competitive Landscape

Bone Biologics faces intense competition from larger, well-established companies with greater resources.

Growth Trajectory and Initiatives

Historical Growth: Limited historical growth due to development stage.

Future Projections: Future growth depends on NBG-002's clinical and commercial success.

Recent Initiatives: Focus on clinical development and potential partnerships.

Summary

Bone Biologics is a high-risk, high-reward development-stage company. Its future depends heavily on the success of NBG-002. The warrants represent an opportunity to participate in potential upside, but also carry significant risk due to the company's financial situation and development stage. Success depends on the company's ability to navigate regulatory hurdles and secure adequate funding.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data, which may be limited.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bone Biologics Corp Warrants

Exchange NASDAQ
Headquaters Burlington, MA, United States
IPO Launch date 2021-10-13
CEO & President Mr. Jeffrey Frelick
Sector Healthcare
Industry Medical Devices
Full time employees 2
Full time employees 2

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.